EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Donanemab: First Approval

Connie Kang

Drugs · 2024

DOI: 10.1007/s40265-024-02087-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2024. Verfasst von Connie Kang. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Approval. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Donanemab (donanemab-azbt; KisunlaTM) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease. Donanemab recently received approval in the USA for the treatment of adults with early symptomatic Alzheimer's disease (patients with mild cognitive impairment or mild dementia stage of disease). This article summarizes the milestones in the development of donanemab leading to this first approval for Alzheimer's disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDrug ApprovalHumansAntibodies, Monoclonal, HumanizedAmyloid beta-PeptidesUnited StatesCognitive DysfunctionUnited States Food and Drug Administration

Substanzen

Antibodies, Monoclonal, HumanizedAmyloid beta-Peptidesdonanemab

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Kang, C. (2024). Donanemab: First Approval. Drugs. https://doi.org/10.1007/s40265-024-02087-4

Vancouver

Kang C. Donanemab: First Approval. Drugs. 2024. doi:10.1007/s40265-024-02087-4

BibTeX
@article{Kang2024,
  author = {Kang, Connie},
  title = {Donanemab: First Approval},
  journal = {Drugs},
  year = {2024},
  doi = {10.1007/s40265-024-02087-4}
}
Kostenlos starten →